Nitridergic Modulation of COX-2 Efficacy

Simple item page
dc.contributor.authorMiranda, Hugo
dc.contributor.authorNoriega, Viviana
dc.contributor.authorMoreno, Francisca
dc.contributor.authorSierralta, Fernando
dc.contributor.authorSotomayor, Ramón
dc.contributor.authorPrieto, Juan
dc.date.accessioned2022-09-13T15:11:38Z
dc.date.available2022-09-13T15:11:38Z
dc.date.issued2022
dc.description.abstractPain is a common unpleasant sensory and emotional experience, in which are frequently used in their treatment the nonsteroidal anti-inflammatory drugs (NSAIDs). A group of agents with antipyretic, analgesic, and anti-inflammatory properties due to the inhibition of cyclooxygenase enzymes (COXs). Among these drugs there are a group of selective inhibitors of COX-2 named coxib that include to parecoxib, celecoxib, rofecoxib and etoricoxib. Pharmacological information on the mechanism of action of coxibs is insufficient to determine the analgesic and anti-inflammatory efficacy of these agents. There are contradictory reports regarding the antinociceptive effects of the various coxibs at the preclinical level as well as the nitridergic modulation of such actions. The objective of the present study was to evaluate the antinociceptive efficacy of parecoxib, rofecoxib, celecoxib, and etoricoxib using the formalin hind paw assay in mice and the possible contribution of the nitridergic system in the efficacy of COX-2 agents. Antinociception was assessed in a murine formalin assay using dose-response curves to coxibs before and after i.p. administration of 5 mg/kg of L-NAME. Coxibs produced dose-dependent analgesia and anti-inflammation. L-NAME administration reduced the analgesic and anti-inflammatory effectiveness of parecoxib, rofecoxib, celecoxib, and etoricoxib. These findings suggest that the effect of these agents, in addition to COX-2 inhibition, would be mediated by other mechanisms, among which nitridergic modulation would be compromised.es
dc.description.versionVersión publicadaes
dc.identifier.citationNoradrenergic modulation of Dex-ketoprofen analgesia in preclinical orofacial pain.International Journal of Frontiers in Biology and Pharmacy Research. 2022;03(01)(01):01. doi:10.53294/ijfbpr.2022.3.1.0053es
dc.identifier.urihttps://doi.org/10.30574/wjarr.2022.15.2.0784es
dc.identifier.urihttp://hdl.handle.net/11447/6576
dc.language.isoenes
dc.subjectCoxibes
dc.subjectCOX-2es
dc.subjectCOX-2es
dc.subject; L-NAMEes
dc.subjectFormalin testes
dc.subjectAntinociceptiones
dc.titleNitridergic Modulation of COX-2 Efficacyes
dc.typeArticlees
dcterms.sourceInternational Journal of Frontiers in Biology and Pharmacy Researches

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Nitridergic Modulation of COX-2 Efficacy.pdf
Size:
823.96 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services